SAB Biotherapeutics, Inc. (SABS)
3.715
-0.08
(-1.98%)
USD |
NASDAQ |
Aug 31, 16:00
3.715
0.00 (0.00%)
After-Hours: 17:40
SAB Biotherapeutics Debt to Equity Ratio : 0.0239 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0239 |
| March 31, 2026 | 0.0272 |
| December 31, 2025 | 0.0393 |
| September 30, 2025 | 0.0375 |
| June 30, 2025 | 0.5342 |
| March 31, 2025 | 0.3169 |
| December 31, 2024 | 0.1798 |
| September 30, 2024 | 0.1225 |
| June 30, 2024 | 0.1158 |
| March 31, 2024 | 0.1032 |
| December 31, 2023 | 0.1031 |
| September 30, 2023 | 0.305 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.2487 |
| March 31, 2023 | 0.2238 |
| December 31, 2022 | 0.1909 |
| September 30, 2022 | 0.1895 |
| June 30, 2022 | 0.1641 |
| March 31, 2022 | 0.1554 |
| December 31, 2021 | 0.2209 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 9.375 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 238.21M |
| Total Liabilities (Quarterly) | 23.42M |
| Shareholders Equity (Quarterly) | 214.78M |
| Current Ratio | 9.221 |
| Net Debt Paydown Yield | 0.10% |